Smoking, atrial fibrillation, and ischemic stroke: a confluence of epidemics : Current Opinion in Cardiology

Secondary Logo

Journal Logo

PREVENTION: Edited by Andrew Pipe

Smoking, atrial fibrillation, and ischemic stroke

a confluence of epidemics

Albertsen, Ida Ehlersa; Overvad, Thure Filskovb; Lip, Gregory Y.H.b,c; Larsen, Torben Bjerregaarda,c

Author Information
Current Opinion in Cardiology 30(5):p 512-517, September 2015. | DOI: 10.1097/HCO.0000000000000205
  • Free



Atrial fibrillation is the most common cardiac arrhythmia and a frequent and devastating cause of morbidity and mortality from cardioembolic stroke [1,2]. The prevalence of atrial fibrillation has taken a daunting rise. It is expected to reach pandemic proportions due to the continued aging of the general population [3▪▪]. Atrial fibrillation may be prevalent in up to 1/3 of all patients with incident ischemic stroke [4▪].

One potential factor involved in the pathogenesis of atrial fibrillation is smoking [5–8]. Smoking causes a broad range of oncogenic [9], cardiovascular [10], cerebrovascular [10], and respiratory disease. Unfortunately, smoking continues to be a dominant health hazard worldwide and responsible for major healthcare costs [11].

The purpose of the current article is to describe recent scientific investigations linking the epidemics of smoking, atrial fibrillation, and ischemic stroke, with a primary focus on prevention strategies.

Box 1:
no caption available


Smoking predisposes to atrial fibrillation [6,12–14] in a dose–response manner [15▪▪]. Possible mediators include diabetes mellitus [16▪], chronic obstructive pulmonary disease/impaired lung function [17▪,18], hypertension, and heart failure – all diseases that are likely to be caused by smoking [19▪▪], and which in turn can induce atrial fibrillation [15▪▪]. In addition, smoking also causes structural remodeling of the myocardium, which has direct toxic effects on the conductive properties and may lead to atrial fibrillation [15▪▪,20]. Continued tobacco use is also associated with atrial fibrillation after catheter ablation [15▪▪].


Smoking status has also proven valuable for the prediction of future atrial fibrillation. Among five other variables, smoking status is included in the Women's Health Study Atrial Fibrillation risk prediction algorithm identifying women at higher risk for incident atrial fibrillation [21] (see Table 1 for risk prediction models covered in this article).

Table 1:
Components of various risk prediction models for use in patients with atrial fibrillation that include information on smoking habits

In the Cohorts for Heart and Aging Research in Genomic Epidemiology - Atrial Fibrillation model for the prediction of incident atrial fibrillation, current smoking status is included as a component adding predictive ability independent of other traditional cardiovascular-risk predictors such as age, race, height, weight, systolic and diastolic blood pressure, use of antihypertensive medication, diabetes, and history of myocardial infarction and heart failure [22▪▪,23]. In summary, smoking not only causes atrial fibrillation, but smoking status also aids in the identification of people at high risk of future incident atrial fibrillation.


How can we reduce the combined burden caused by the confluence of smoking and atrial fibrillation? Two approaches are immediately evident. First, as smoking predisposes to atrial fibrillation, primary prevention of atrial fibrillation is partly achieved through smoking cessation. Secondly, improving the identification of patients with established atrial fibrillation who stand to gain most from anticoagulant treatment is essential. This is currently provided through the use of risk stratification models used for the prediction of thromboembolic events and anticoagulant-related bleeding in patients with incident atrial fibrillation. The stratification models used for the prediction of thromboembolic events will be briefly introduced in the following section.


Anticoagulant therapy, when used appropriately, has a dramatic effect on the prevention of thromboembolic events – preventing approximately two-thirds of all atrial fibrillation-related strokes [24]. Although anticoagulant treatment is highly preventive, not all patients stand to gain. Despite the overall advantage in reducing the risk of stroke, anticoagulant therapy is a double-edged sword, with an inherent risk of potentially fatal bleeding.


The risk of thromboembolic events is not homogeneous, but varies according to the presence or absence of various lifestyle and clinical-risk factors. These risk factors have formed the basis for stroke-risk stratification schemes and clinical practice guidelines for stroke prevention in patients with atrial fibrillation. The purpose of these schemes is to identify patients who could benefit from oral anticoagulation.

In recent international guidelines [25,26], the CHA2DS2-VASc score [Cardiac failure or dysfunction, Hypertension, Age ≥75 (doubled), Diabetes, Stroke (doubled)-Vascular disease, Age 65–74 and Sex category (Female)] score [27] is recommended as a risk stratification tool for all patients with atrial fibrillation. It is advocated that all patients with a single risk factor from the CHA2DS2-VASc score (except women with female sex as their only risk factor) should be considered for preventive anticoagulant treatment. Despite these clear guideline recommendations, many atrial fibrillation patients do not receive oral anticoagulation as often as is clinically indicated [4▪,28▪]. It has been suggested that physicians may overestimate bleeding risk from oral anticoagulation and underestimate its benefits in stroke prevention [29].

When oral anticoagulation with adjusted-dose vitamin K antagonists is used, the quality of anticoagulation control, as reflected by the time in therapeutic range of the international normalized ratio (INR), is an important determinant of risk of thromboembolism and bleeding [30,31]. The Sex [female], Age<60, Medical history, Treatment [interacting drugs], Tobacco use, Race [non-white] (SAMe-TT2R2) score is a scheme made to assess the likelihood of poor INR control among atrial fibrillation patients receiving vitamin K antagonists using patient-related clinical parameters [32] (Table 1). One of the features found to be associated with poor INR control is tobacco use, and this is given double weight in this risk stratification model. Hence, a patient with incident atrial fibrillation who smokes and has an indication for anticoagulant treatment may benefit most from treatment with one of the non-vitamin K antagonist oral anticoagulants (NOACs).


There is an on-going interest in improving the existing thromboembolic-risk prediction models, and recent studies have focused on smoking behavior. Using data from the population-based Diet, Cancer and Health study, a recent investigation explored the potential improvement of prediction of thromboembolic events and death in 3161 patients with incident atrial fibrillation using information on smoking status [33▪]. After adjustment for components of the CHA2DS2-VASc score and time-varying use of anticoagulant therapy during follow-up, both former and current smokers remained at higher risk of thromboembolism or death in what resembled a dose–response-dependent manner. That smokers represent a high-risk population, also in the setting of atrial fibrillation, should not come as a surprise. The new and interesting evidence provided here is the possible added predictive value to the currently recommended risk stratification tool, the CHA2DS2-VASc score. Despite the CHA2DS2-VASc including several components that are likely to act as mediators between smoking and thromboembolic events and death (hypertension, heart failure, diabetes mellitus, previous stroke, and vascular disease), smoking status was clearly capable of identifying patients at high risk of future adverse events. This might improve the identification of patients with atrial fibrillation at high risk of thromboembolic events, and thereby increase the use of appropriate anticoagulant treatment in atrial fibrillation. Importantly, the analysis from the Diet, Cancer and Health cohort is a study of prediction, not causality. Therefore, a conclusion of a beneficial effect of smoking cessation on future risk of adverse events in those with atrial fibrillation (although theoretically highly likely) cannot be drawn from the study.

Others have since confirmed the findings from the Danish cohort. In a recent Japanese study, Nakagawa et al.[34▪] investigated patients already diagnosed with atrial fibrillation and the impact of smoking on the following long-term outcomes: all-cause death, stroke (ischemic and hemorrhagic), cardiac events (myocardial infarction or hospitalization for worsening of heart failure), bleeding (gastrointestinal and intracranial hemorrhages), and cardiovascular event (stroke and cardiac event). They found that a history of smoking, independently of age, antithrombotic treatment and CHADS2 and CHA2DS2-VASc scores, predicted all-cause mortality, death from stroke or death from malignant diseases. Persistent smoking, independently of age or antithrombotic treatment, also predicted intracranial bleeding. Hence, smoking status clearly identifies patients with atrial fibrillation at high risk of subsequent ischemic stroke, but may also identify patients at risk of bleeding during anticoagulant treatment.

The QStroke score is an algorithm developed to estimate the risk of incident stroke or transient ischemic attack [35]. It has been validated in populations both with and without atrial fibrillation. It includes major risk factors for cardiovascular disease, including information on smoking divided into five levels. Interestingly, they compare the algorithm with the CHA2DS2-VASc score in patients with atrial fibrillation. Investigators have demonstrated some evidence of statistically improved discriminatory performance of QStroke compared with the CHA2DS2-VASc score. However, the QStroke algorithm is unlikely to replace the CHA2DS2-VASc score for the prediction of thromboembolic events due to its major degree of complexity compared with the CHA2DS2-VASc score.


Another recently introduced risk stratification tool is the Risk Estimator Decision Aid for Atrial Fibrillation (RED-AF) model for estimating risk of experiencing a 30-day adverse event in patients with atrial fibrillation admitted to an emergency department [36,37]. RED-AF was derived from a cohort of 832 patients. It assigns points according to smoking status and to age, sex, coexisting disease (e.g., heart failure, hypertension, and chronic obstructive pulmonary disease), medication use (e.g., beta-blockers, diuretics, etc.), physical examination findings (e.g., dyspnea, palpitations, and peripheral edema), and adequacy of emergency department ventricular rate control. Atrial fibrillation combined with just one of these risk factors was independently associated with an adverse event: 30-day emergency department return visit, unscheduled hospitalization, cardiovascular complication, or death. The decision to hospitalize patients with atrial fibrillation is often subjective and multifactorial, according to the patient's acute and chronic conditions. Emergency physicians need to feel confident identifying stable, low-risk patients with atrial fibrillation. The tool is supposed to help guide emergency physicians on which patients with atrial fibrillation can be safely managed as outpatients and which should be hospitalized.


Smoking is a major preventable cause of ischemic stroke. Importantly, though, several subtypes of ischemic stroke exist, for which the optimal preventive pharmacological approach may vary [38]. In the general population, smoking causes mainly strokes that are atherothrombotic in nature, whereas strokes caused by atrial fibrillation are of cardioembolic origin. Future studies should address whether the smoking behavior of patients with atrial fibrillation is indeed predictive of cardioembolic stroke, as these strokes are preferably prevented by oral anticoagulant treatment, whereas strokes of atherothrombotic nature are likely to be reduced primarily by the use of antiplatelet therapy [39]. If the higher risk of ischemic stroke seen in atrial fibrillation patients who smoke can be attributed to a higher risk of cardioembolic stroke, and not only atherothrombotic stroke, this would clearly establish smoking status as a patient characteristic favoring oral anticoagulant treatment.


Given the current investigations of smoking status as an important risk predictor in patients with atrial fibrillation [33▪,34▪], its potential additive predictive value to the CHA2DS2-VASc score merits further investigation. Further studies are needed to confirm the relationship between smoking status and risk of cardioembolic stroke in patients with atrial fibrillation, as this may subsequently inform decision-making regarding anticoagulant treatment in everyday clinical practice. Whether smoking status clearly favors the initiation of anticoagulant treatment depends also on the degree of anticoagulant-related bleeding in these patients. Further studies investigating the net clinical benefit of anticoagulant treatment in patients with atrial fibrillation and a history of smoking are needed.


Smoking is clearly an important patient characteristic among those with atrial fibrillation. From an etiologic perspective, prevention of incident smoking and promotion of smoking cessation would prevent incident cases of atrial fibrillation. Additionally, smoking status is a critical patient feature in the prediction of the many adverse events related to atrial fibrillation. The identification of smoking status permits the prediction of incident atrial fibrillation, adverse events in an emergency ward after admission with atrial fibrillation, thromboembolic events following a diagnosis of atrial fibrillation, and potentially poor control of vitamin K antagonist treatment. Patients who smoke represent a high-risk population from many angles of adversity related to the growing epidemic of atrial fibrillation. Appropriate measures of prevention targeting this endangered population are called for.



Financial support and sponsorship


Conflicts of interest

TBL has served as an investigator for Janssen Scientific Affairs, LLC, and Boehringer Ingelheim and has been on the speaker bureaus for Bayer, BMS/Pfizer, Janssen Pharmaceuticals, Takeda, Roche Diagnostics, and Boehringer Ingelheim. GYHL has served as a consultant for Bayer, Astellas, Merck, Sanofi, BMS/Pfizer, Daiichi-Sankyo, Biotronik, Portola, and Boehringer Ingelheim and has served as a speaker for Bayer, BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, and Sanofi Aventis. The remaining authors have no conflicts of interest.


Papers of particular interest, published within the annual period of review, have been highlighted as:

  • ▪ of special interest
  • ▪▪ of outstanding interest


1. Benjamin EJ, Wolf PA, D’Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98:946–952.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22:983–988.
3▪▪. Yiin GS, Howard DP, Paul NL, et al. Age-specific incidence, outcome, cost, and projected future burden of atrial fibrillation-related embolic vascular events: a population-based study. Circulation 2014; 130:1236–1244.

Up-to-date projections of the future subtantial burden of atrial fibrillation-related cardioembolic events.

4▪. Friberg L, Rosenqvist M, Lindgren A, et al. High prevalence of atrial fibrillation among patients with ischemic stroke. Stroke 2014; 45:2599–2605.

Study underlining the heavy impact of atrial fibrillation on the total burden of ischemic stroke in the population.

5. Chamberlain AM, Agarwal SK, Folsom AR, et al. Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) study. Heart Rhythm 2011; 8:1160–1166.
6. Heeringa J, Kors JA, Hofman A, et al. Cigarette smoking and risk of atrial fibrillation: the Rotterdam study. Am Heart J 2008; 156:1163–1169.
7. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up study. Am J Med 1995; 98:476–484.
8. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA 1994; 271:840–844.
9. Kenfield SA, Stampfer MJ, Rosner BA, et al. Smoking and smoking cessation in relation to mortality in women. JAMA 2008; 299:2037–2047.
10. Ockene IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. Circulation 1997; 96:3243–3247.
11. The Gallup Organisation, Hungary. Flash Eurobarometer No 253. Survey on Tobacco. Analytical report, 2009. European Commission website: [Accessed 7 April, 2015]
12. Suzuki S, Otsuka T, Sagara K, et al. Association between smoking habits and the first-time appearance of atrial fibrillation in Japanese patients: evidence from the Shinken Database. J Cardiol 2014; doi: 10.1016/j.jjcc.2014.09.010. [Epub ahead of print].
13. Suzuki S, Sagara K, Otsuka T, et al. Effects of smoking habit on the prevalence of atrial fibrillation in Japanese patients with special reference to sex differences. Circ J 2013; 77:2948–2953.
14. Lee SH, Park S-J, Byeon K, et al. Risk factors between patients with lone and nonlone atrial fibrillation. J Korean Med Sci 2013; 28:1174–1180.
15▪▪. Andrade J, Khairy P, Dobrev D, et al. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res 2014; 114:1453–1468.

Thorough review of the pathophysiology of atrial fibrillation, which also includes review of smoking as a potential cause.

16▪. Spijkerman A, van der A DL, Nilsson PM, et al. Smoking and long-term risk of type 2 diabetes: the EPIC-InterAct study in European populations. Diabetes Care 2014; 37:3164–3171.

Large-scale cohort study linking smoking with the development of type 2 diabetes mellitus.

17▪. Li J, Agarwal SK, Alonso A, et al. Airflow obstruction, lung function, and incidence of atrial fibrillation: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 2014; 129:971–980.

Study linking smoking with incident atrial fibrillation through obstructive lung disease.

18. Johnson LS, Juhlin T, Engstrom G, et al. Reduced forced expiratory volume is associated with increased incidence of atrial fibrillation: the Malmo Preventive Project. Europace 2014; 16:182–188.
19▪▪. Carter BD, Abnet CC, Feskanich D, et al. Smoking and mortality: beyond established causes. N Engl J Med 2015; 372:631–640.

Updated review of the list of diseases potentaially caused by smoking.

20. D’Alessandro A, Boeckelmann I, Hammwhoner M, et al. Nicotine, cigarette smoking and cardiac arrhythmia: an overview. Eur J Prev Cardiol 2012; 19:297–305.
21. Everett BM, Cook NR, Conen D, et al. Novel genetic markers improve measures of atrial fibrillation risk prediction. Eur Heart J 2013; 34:2243–2251.
22▪▪. Pfister R, Brägelmann J, Michels G, et al. Performance of the CHARGE-AF risk model for incident atrial fibrillation in the EPIC Norfolk cohort. Eur J Prev Cardiol 2015; 22:932–939.

Validation of a risk model for prediction of incident atrial fibrillation that includes information about smoking habits.

23. Alonso A, Krijthe BP, Aspelund T, et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc 2013; 2:1–11.
24. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857–867.
25. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64:e1–e76.
26. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012; 33:2719–2747.
27. Lip GY, Frison L, Halperin JL, et al. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010; 41:2731–2738.
28▪. Huang B, Yang Y, Zhu J, et al. Clinical characteristics and prognostic significance of chronic obstructive pulmonary disease in patients with atrial fibrillation: results from a multicenter atrial fibrillation registry study. J Am Med Dir Assoc 2014; 15:576–581.

Study linking smoking to mortality in patients with atrial fibrillation through chronic obstructive pulmonary disease.

29. Jespersen SF, Christensen LM, Christensen A, et al. Use of oral anticoagulation therapy in atrial fibrillation after stroke: results from a nationwide registry. Thrombosis 2013; 2013:601450.
30. Gallego P, Roldan V, Marín F, et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013; 110:1189–1198.
31. De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position Paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110:1087–1107.
32. Apostolakis S, Sullivan RM, Olshansky B, et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest 2013; 144:1555–1563.
33▪. Albertsen IE, Rasmussen LH, Lane DA, et al. The impact of smoking on thromboembolism and mortality in patients with incident atrial fibrillation: insights from the Danish Diet, Cancer, and Health study. Chest 2014; 145:559–566.

The first study to show that smoking status predicts thromboembolism and mortality in patients with atrial fibrillation.

34▪. Nakagawa K, Hirai T, Ohara K, et al. Impact of persistent smoking on long-term outcomes including bleeding events in patients with nonvalvular atrial fibrillation. J Cardiol 2015; 65:429–433.

Study showing that smoking status is predictive of mortality, stroke mortality and bleeding in patients with established atrial fibrillation.

35. Hippisley-Cox J, Coupland C, Brindle P. Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. BMJ 2013; 346:f2573.
36. Barrett TW, Jenkins CA, Self WH. Validation of the Risk Estimator Decision Aid for Atrial Fibrillation (RED-AF) for predicting 30-day adverse events in emergency department patients with atrial fibrillation. Ann Emerg Med 2015; 65:13–21.e3.
37. Barrett TW, Martin AR, Storrow AB, et al. A clinical prediction model to estimate risk for 30-day adverse events in emergency department patients with symptomatic atrial fibrillation. Ann Emerg Med 2011; 57:1–12.
38. Adams H, Adams H, Bendixen B, et al. Classification of subtype of acute ischemic stroke. Stroke 1993; 23:35–41.
39. Rajkumar C, Floyd C, Ferro A. Antiplatelet therapy as a modulator of stroke aetiology: a meta-analysis. Br J Clin Pharmacol 2015; doi: 10.1111/bcp.12630. [Epub ahead of print].

atrial fibrillation; prevention; smoking; stroke

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.